Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03868904 · ClinicalTrials.gov registry record
INSPIRE Continuation Post-Approval Study
A clinical trial of Bronchiolitis Obliterans, sponsored by TransMedics.
- Completed
- Registry status
- 220
- Enrollment target
- 17
- Study locations
NCT03868904: Completed study of Bronchiolitis Obliterans, sponsored by TransMedics.
NCT03868904 is a study of Bronchiolitis Obliterans that has completed, run by TransMedics. The registered enrollment target is 220 participants, below the 384-participant average among 9 other Bronchiolitis Obliterans trials with a reported enrollment target (43% lower). The trial reports 17 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03868904, a study of Bronchiolitis Obliterans, has completed, sponsored by TransMedics.
- COMPLETED
- Registry status
- 220 participants
- Enrollment target
- 17
- Study locations
Study Summary
To evaluate long-term BOS-free survival outcomes of the OCS™ Lung INSPIRE Trial patients.
Primary Outcome
BOS-free survival
Conditions Studied
Interventions
- DEVICE OCS Lung System
Study Locations (17)
Other
- University of Leuven Hospital - Leuven
- N.H.C Hospital Civil - Strasbourg
- German Heart Institute Berlin - Berlin
- Hannover Medical School - Hanover
- University of Padua - Padua
- Hospital Universitario Puerta De Hierro - Madrid
- Papworth Hospital - Cambridge
- Harefield Hospital - Middlesex
California
- UCLA Medical Center - Los Angeles
- University of California at San Francisco - San Francisco
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
Indiana
- Indiana University - Indianapolis
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- University of Minnesota - Minneapolis
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
New South Wales
- St. Vincent's Hospital - Darlinghurst
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2019-06-30 |
| Est. Completion | 2021-10-12 |
What the finished NCT03868904 record still lists
NCT03868904 is an observational study that tracks outcomes without assigning an intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 384-participant average among 9 other Bronchiolitis Obliterans trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Bronchiolitis Obliterans appearing as the primary indexed condition, and to 1 intervention - of which OCS Lung System is the first listed.
NCT03868904 lists 17 locations in 9 states (Other, California, Arizona).
Frequently Asked Questions
What is clinical trial NCT03868904 about?
NCT03868904 is a clinical study titled "INSPIRE Continuation Post-Approval Study". To evaluate long-term BOS-free survival outcomes of the OCS™ Lung INSPIRE Trial patients.
What is the current status of trial NCT03868904?
This trial is currently completed. The enrollment target is 220 participants. The study started on 2019-06-30. Estimated completion is 2021-10-12.
What conditions does trial NCT03868904 study?
This clinical trial studies the following conditions: Bronchiolitis Obliterans.
What interventions are being tested in trial NCT03868904?
The interventions under investigation include: OCS Lung System (DEVICE).
Who is sponsoring clinical trial NCT03868904?
This trial is sponsored by TransMedics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03868904 being conducted?
This trial has 17 study locations across Arizona, California, Indiana, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bronchiolitis Obliterans
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03868904's enrollment target sits among peer trials
220 4th of 9 higher than 6 of 9 other Bronchiolitis Obliterans trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bronchiolitis Obliterans trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
RECRUITING
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
-
Evaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans Syndrome
RECRUITING
-
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
COMPLETED · Phase 3
-
Hp129 Xenon Imaging and BOS in Lung Transplantation
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI